{"protocolSection": {"identificationModule": {"nctId": "NCT00700271", "orgStudyIdInfo": {"id": "CVAA489AFR01"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day", "officialTitle": "Efficacy of a Combination of Amlodipine / Valsartan on Blood Pressure Control, With One Nocturnal or Diurnal Intake a Day, in Ambulatory Blood Pressure Monitoring Setting, in Essential Uncontrolled Hypertensive Patients With Amlodipine 5mg ; The ExPERT Study"}, "statusModule": {"statusVerifiedDate": "2011-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-10"}, "primaryCompletionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-11", "studyFirstSubmitQcDate": "2008-06-17", "studyFirstPostDateStruct": {"date": "2008-06-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-15", "resultsFirstSubmitQcDate": "2010-12-15", "resultsFirstPostDateStruct": {"date": "2011-01-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-05-16", "lastUpdatePostDateStruct": {"date": "2011-05-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study was a multicenter, randomized, PROBE-type (prospective, randomized, open label, blinded end-point) study of 12 weeks duration comprising four visits, carried out in patients with essential arterial hypertension not controlled on four weeks treatment with amlodipine 5 mg alone."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "ambulatory blood pressure monitoring"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 478, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Morning Intake", "type": "EXPERIMENTAL", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.", "interventionNames": ["Drug: Amlodipine", "Drug: Valsartan"]}, {"label": "Evening Intake", "type": "EXPERIMENTAL", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.", "interventionNames": ["Drug: Amlodipine", "Drug: Valsartan"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine", "description": "5 mg or 10 mg tablets.", "armGroupLabels": ["Evening Intake", "Morning Intake"]}, {"type": "DRUG", "name": "Valsartan", "description": "160 mg capsules.", "armGroupLabels": ["Evening Intake", "Morning Intake"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Reduction From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)"}], "secondaryOutcomes": [{"measure": "Absolute Reduction From Baseline in Diurnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)"}, {"measure": "Absolute Reduction From Baseline in Nocturnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)"}, {"measure": "Absolute Reduction From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)"}, {"measure": "Absolute Reduction From Baseline in 6-hour Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)"}, {"measure": "Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) Variation Between Week 0 and Week 8 in Office Blood Pressure", "description": "At each of the office visits, blood pressure was recorded in the morning between 08.00 and 11.00, before any antihypertensive treatment was taken. The patient remained in a sitting position for five minutes; the investigator then took three blood pressure and one pulse rate reading. The measurements were recorded at 1-2 minute intervals. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)"}, {"measure": "Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) Variation Between Week -4 to Week 8 in Office Blood Pressure", "description": "At each of the office visits, blood pressure was recorded in the morning between 08.00 and 11.00, before any antihypertensive treatment was taken. The patient remained in a sitting position for five minutes; the investigator then took three blood pressure and one pulse rate reading. The measurements were recorded at 1-2 minute intervals. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "timeFrame": "Screening visit (Week -4, prior to 4-week open-label screening phase) and Week 8 (after 8 weeks of combination therapy)"}, {"measure": "Percentage of Participants With 24-hour Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 125/80 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken.", "timeFrame": "Visit 4 (week 8)"}, {"measure": "Percentage of Participants With Diurnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 135/85 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken.", "timeFrame": "Visit 4 (week 8)"}, {"measure": "Percentage of Participants With Nocturnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 120/70 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken.", "timeFrame": "Visit 4 (week 8)"}, {"measure": "Percentage of Participants With Controlled Office Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) at Endpoint", "description": "At each of the office visits, blood pressure was recorded in the morning between 08.00 and 11.00, before any antihypertensive treatment was taken. The patient remained in a sitting position for 5 minutes; the investigator then took 3 blood pressure and 1 pulse rate reading. The measurements were recorded at 1-2 minute intervals. BP Control is defined as msSBP/msDBP \\<149/90 mmHg and/or \\<130/80 mmHg if diabetes or renal insufficiency (RI).", "timeFrame": "Visit 4 (week 8)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\>= 18 years\n* Essential uncontrolled or naive hypertensive patients (SBP \u2265= 140 mmHG, DBP - \\>/=90 mm Hg, or SBP \\>= 130 mmHg, DBP \\>= 80 mmHg if diabetes or renal impairment) except patients treated with amlodipine, or intolerant of ARBs and/or calcium channel blockers.\n\nExclusion Criteria:\n\n* Severe hypertension : SBP \\>= 180 mmHg, DBP \\>= 110mmHg\n* Pregnancy\n* Allergia to ARBs and/or to calcium channel blockers\n* Antihypertensive tritherapy at V1\n* History of heart failure, pectoris angina, stroke, myocardial infarction\n* Diabetes type I\n* Renal impairment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Roland Asmar", "affiliation": "principle investigator; Institut cardiovasculaire 75016 Paris", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Investigative sites in France", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Investigative sites in Tunisia", "city": "Tunisia", "country": "Tunisia"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Eligible patients entered a 4-week open-label amlodipine screening phase with amlodipine 5 mg taken orally once a day. At the end of the screening phase, patients whose blood pressure was not adequately controlled (defined as SBP/DBP \\>= 125/80 mmHg 24-hr mean) on ambulatory blood pressure monitoring were randomized to one of two treatment groups.", "groups": [{"id": "FG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "FG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "278"}, {"groupId": "FG001", "numSubjects": "268"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "264"}, {"groupId": "FG001", "numSubjects": "256"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Administrative Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "BG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "242"}, {"groupId": "BG001", "value": "237"}, {"groupId": "BG002", "value": "479"}]}], "measures": [{"title": "Age Continuous", "description": "Demographic data is provided for the Intent-to-Treat population, which included all the patients randomized and treated in the study and for whom two ABPM evaluations were available.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.8", "spread": "9.89"}, {"groupId": "BG001", "value": "56.2", "spread": "9.59"}, {"groupId": "BG002", "value": "56.0", "spread": "9.74"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "114"}, {"groupId": "BG001", "value": "111"}, {"groupId": "BG002", "value": "225"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "128"}, {"groupId": "BG001", "value": "126"}, {"groupId": "BG002", "value": "254"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Reduction From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.01", "spread": "0.70"}, {"groupId": "OG001", "value": "-11.3", "spread": "0.71"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Reduction From Baseline in Diurnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"title": "Systolic Blood Pressure (SBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.50", "spread": "0.78"}, {"groupId": "OG001", "value": "-11.99", "spread": "0.8"}]}]}, {"title": "Diastolic Blood Pressure (DBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.56", "spread": "0.49"}, {"groupId": "OG001", "value": "-7.11", "spread": "0.5"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Reduction From Baseline in Nocturnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"title": "Systolic Blood Pressure (SBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.68", "spread": "0.74"}, {"groupId": "OG001", "value": "-10.33", "spread": "0.76"}]}]}, {"title": "Diastolic Blood Pressure (DBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.01", "spread": "0.46"}, {"groupId": "OG001", "value": "-6.3", "spread": "0.47"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Reduction From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.53", "spread": "0.42"}, {"groupId": "OG001", "value": "-6.79", "spread": "0.43"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Reduction From Baseline in 6-hour Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit 2 was carried out prior to randomization and the first dose of the amlodipine/valsartan combination study therapy. ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"title": "Systolic Blood Pressure (SBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.16", "spread": "0.88"}, {"groupId": "OG001", "value": "-11.37", "spread": "0.90"}]}]}, {"title": "Diastolic Blood Pressure (DBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.71", "spread": "0.59"}, {"groupId": "OG001", "value": "-7.01", "spread": "0.60"}]}]}]}, {"type": "SECONDARY", "title": "Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) Variation Between Week 0 and Week 8 in Office Blood Pressure", "description": "At each of the office visits, blood pressure was recorded in the morning between 08.00 and 11.00, before any antihypertensive treatment was taken. The patient remained in a sitting position for five minutes; the investigator then took three blood pressure and one pulse rate reading. The measurements were recorded at 1-2 minute intervals. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline (Week 0, after completion of screening period) and Week 8 (after 8 weeks of combination therapy)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "231"}, {"groupId": "OG001", "value": "232"}]}], "classes": [{"title": "Systolic Blood Pressure (SBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.7", "spread": "0.9"}, {"groupId": "OG001", "value": "-17.3", "spread": "0.9"}]}]}, {"title": "Diastolic Blood Pressure (DBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.1", "spread": "0.6"}, {"groupId": "OG001", "value": "-8.6", "spread": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) Variation Between Week -4 to Week 8 in Office Blood Pressure", "description": "At each of the office visits, blood pressure was recorded in the morning between 08.00 and 11.00, before any antihypertensive treatment was taken. The patient remained in a sitting position for five minutes; the investigator then took three blood pressure and one pulse rate reading. The measurements were recorded at 1-2 minute intervals. Covariates included baseline level, country, up-titration + treatment\\*country and treatment\\*up-titration interactions in case statistically significant at a 0.10 level.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Screening visit (Week -4, prior to 4-week open-label screening phase) and Week 8 (after 8 weeks of combination therapy)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "231"}, {"groupId": "OG001", "value": "232"}]}], "classes": [{"title": "Systolic Blood Pressure (SBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-32.2", "spread": "1.1"}, {"groupId": "OG001", "value": "-29", "spread": "1.2"}]}]}, {"title": "Diastolic Blood Pressure (DBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.6", "spread": "0.8"}, {"groupId": "OG001", "value": "-14.3", "spread": "0.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With 24-hour Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 125/80 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Visit 4 (week 8)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47.6"}, {"groupId": "OG001", "value": "46.9"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Diurnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 135/85 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Visit 4 (week 8)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "65.3"}, {"groupId": "OG001", "value": "58.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Nocturnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 120/70 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring", "description": "Ambulatory Blood Pressure Monitoring (ABPM) over a 30-hour period was carried out in all patients at two visits during the study, 72 hours before visit 2 (baseline) and visit 4 (week 8). ABPM for visit four began after 12 weeks of treatment and before the last office blood pressure was taken.", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Visit 4 (week 8)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41.3"}, {"groupId": "OG001", "value": "46.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Controlled Office Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) at Endpoint", "description": "At each of the office visits, blood pressure was recorded in the morning between 08.00 and 11.00, before any antihypertensive treatment was taken. The patient remained in a sitting position for 5 minutes; the investigator then took 3 blood pressure and 1 pulse rate reading. The measurements were recorded at 1-2 minute intervals. BP Control is defined as msSBP/msDBP \\<149/90 mmHg and/or \\<130/80 mmHg if diabetes or renal insufficiency (RI).", "populationDescription": "The Intent-to-treat (ITT) population included all patients randomized and treated in the study and for whom two Ambulatory Blood Pressure Monitoring (ABPM) evaluations are available.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Visit 4 (week 8)", "groups": [{"id": "OG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}, {"id": "OG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "71.1"}, {"groupId": "OG001", "value": "72.6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Morning Intake", "description": "After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.", "seriousNumAffected": 2, "seriousNumAtRisk": 278, "otherNumAffected": 0, "otherNumAtRisk": 278}, {"id": "EG001", "title": "Evening Intake", "description": "After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg or msSBP \\>= 130 mmHg and/or msDBP \\>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \\< 140 mmHg and msDBP \\< 90 mmHg or msSBP \\< 130 mmHg and msDBP \\< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.", "seriousNumAffected": 2, "seriousNumAtRisk": 268, "otherNumAffected": 0, "otherNumAtRisk": 268}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 278}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}]}, {"term": "Atrioventricular block", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 278}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 278}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 278}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}]}, {"term": "Sinus tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 278}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 278}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 278}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}]}, {"term": "Stress", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 278}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 278}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or publication of the trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}